InMed Pharmaceuticals Inc S-4/A, filed Sep 29, 2026

InMed Pharmaceuticals Inc. (MTRI)

InMed Pharmaceuticals Inc. proposes to merge with Mentari Therapeutics, Inc., redomesticate from British Columbia, Canada to Nevada and rename itself Mentari Therapeutics, Inc.; Mentari holders are expected to own approximately 99.03% of the combined company on a fully-diluted basis. AI summary